In June 2026, the US FDA banned imports from a Dabur India factory in Dadra and Nagar Haveli. The equipment at the plant worked perfectly. The records lied about how it had been used.
According to inspection findings reported by Reuters and independently confirmed by BioSpace, FDA investigators found that critical manufacturing records had been falsified to conceal that equipment meant for certain products had, in fact, been used to make several others. The company called it a one-off incident affecting a small, low-revenue part of the facility. But the underlying mechanism of the failure is the story this piece is really about: nothing broke. No instrument malfunctioned, no reading drifted out of calibration, no sensor failed. A human decision — recorded, then concealed — is what triggered the sanction.
This is not an isolated pattern. A separate case reported in mid-2026 involved Tentamus India Private Limited, a contract testing laboratory, where FDA inspectors cited a failure to adequately investigate laboratory deviations and documented an attempt to remove analytical documents from the quality control lab while the inspection was still underway. Again: the instruments were not the issue. The documentation trail was.
The Uncomfortable Arithmetic of Data Integrity
Compliance-industry analyses tracking FDA drug GMP warning letters have repeatedly found that data integrity deficiencies — not equipment failure, not manufacturing defects — account for the large majority of citations issued to pharmaceutical manufacturers globally, a pattern that industry publications have described as the single most frequently cited category of violation in recent years. India’s own regulator has been recording a parallel trend domestically. Citing the Economic Survey 2025–26, one industry compliance analysis noted that the Central Drugs Standard Control Organisation (CDSCO) classified 1,879 drug batches as “Not of Standard Quality” in 2025 — more than double the 877 batches flagged in 2024.
Numbers like these invite a natural but slightly wrong question: are Indian instruments getting worse? They are not. What is changing is the volume, complexity, and digital footprint of the data those instruments generate — and regulators’ growing ability to scrutinise not just the result a laboratory reports, but the entire trail of custody behind it. As one 2023 industry analysis in Wiley’s Analytical Science magazine put it, almost every modern measuring device is now digitised by default, and digitisation itself generates enormous quantities of data that most laboratories were never designed to govern. The volume is not the failure. The governance of that volume is where failures live.
A Different Kind of Precision Problem
For a century, laboratory credibility was built almost entirely around instrument precision: could the balance weigh accurately, could the chromatograph separate cleanly, could the spectrometer read consistently. That question still matters. But it is no longer sufficient on its own, and the Dabur case is a clean illustration of why. An analytical instrument has no opinion about what happens to its output after it generates a reading. Whether that reading is timestamped correctly, attributed to the right operator, protected from retrospective editing, and traceable months later to an unbroken chain of custody — none of that is a property of the instrument. It is a property of the data infrastructure wrapped around it: the laboratory information management system (LIMS) tracking the sample, the electronic lab notebook (ELN) documenting the method, the audit trail recording who touched what and when.
This is the central argument this Cover Story returns to across every section that follows: a laboratory’s output is only as trustworthy as the systems that manage its data, not merely the instruments that generate it. Precision answers “was the measurement accurate.” Data infrastructure answers a harder and, increasingly, more consequential question: “can this result be trusted, defended, traced, and reproduced by someone who was not in the room when it was taken.”
Why This Matters Beyond the Inspection Report
It would be a mistake to read the Dabur and Tentamus cases as isolated compliance stories relevant only to regulatory-affairs teams. They are early, visible symptoms of a transition every serious Indian laboratory — pharmaceutical, diagnostic, industrial, academic — is now navigating, whether or not it has a live FDA inspection on its calendar. As Indian laboratories digitise faster, connect more instruments directly to software, and generate more data per sample than a decade ago, the systems responsible for governing that data have shifted from a back-office IT concern to a frontline determinant of whether a laboratory’s work can withstand scrutiny at all.
That shift is what the rest of this Cover Story explores in detail: what the technologies actually managing this transition — LIMS, ELN, connected instruments — actually are and how they are converging into unified platforms; where artificial intelligence genuinely is, and is not yet, doing real work inside that infrastructure; what adoption looks like on the ground in India, interoperability problems included; the very real human and workforce cost of this transition; the regulatory architecture, anchored in India’s own Revised Schedule M, now demanding it; the open legal and ethical questions nobody has fully answered yet; and what all of this looks like specifically in Hyderabad, a city fast becoming one of India’s most consequential laboratory-technology hubs.
The instrument was never the problem. What labs do with what the instrument tells them — that is where trust is built, or quietly lost.
– Sasikiran Kantheti
